Pleased to share that I will be talking at this year's Complement Based Drug Development Summit 1st-3rd Dec, in Boston US. Join us for the latest developments and future visions for complement therapeutics! buff.ly/RqA9bfm #complement #drugdevelopment #innovation

Groundbreaking study suggests causal genetic links between the gut microbiome, immune aging, and macular degeneration. #Microbiome #Aging #Immunology #AMD #GutEyeAxis #Genetics #SystemsBiology #PrecisionMedicine #AgingResearch #Bioinformatics buff.ly/VsWMHYP

New Mendelian randomization study reveals FHR1 and FD as causal drivers in IgA and diabetic nephropathy #Nephrology #KidneyDisease #PrecisionMedicine #Genomics #ComplementSystem #DrugDiscovery #Innovation #ScienceNews #AI #Bioinformatics buff.ly/tfat5dy

New study identifies genetically prioritised plasma proteins as novel therapeutic targets for dry AMD, inc. FHR-4 and FHR-2 #AMD #Ophthalmology #PrecisionMedicine #Proteomics #Genomics #DrugDiscovery #Innovation #ScienceNews #Bioinformatics buff.ly/Q8oaU1e

Transferrin supplementation restores iron balance, prevents ferroptosis, and protects retinal cells, implying a novel therapeutic path for dry AMD. #AMD #Retina #Ophthalmology #Ferroptosis #Transferrin #IronMetabolism #Neuroprotection #CellDeathDisease buff.ly/xt4Anvk

NIH commits $87M to a new Organoid Center—accelerating the shift from animal testing to human-tissue models that could transform drug discovery. #Organoids #DrugDiscovery #Biotech #Innovation #AlternativesToAnimalTesting #TranslationalResearch

MACUSTAR study links structural biomarkers in intermediate AMD (RPD, cRORA) to pathway-specific polygenic risk scores—advancing precision risk stratification & trial design. #AMD #Ophthalmology #Genetics #PolygenicRisk #PrecisionMedicine #VisionResearch buff.ly/SyjrWEg

New study reveals a once “uncertain” CFH variant (p.Pro440Ser) is pathogenic in familial cuticular drusen—linking genetics, complement dysregulation & early macular disease. #Ophthalmology #Genetics #AMD #PrecisionMedicine #RareDisease #VisionResearch buff.ly/wnHCeCI

New study shows #HTRA1 directly disrupts toxic #Tau fibril seeding: a breakthrough in understanding #Alzheimers and opening doors to novel #Neurodegeneration therapies. Understanding HTRA1 biochemistry may unlock what its doing in AMD too. buff.ly/KKyCtNi

Zinc isn’t just a supplement: it’s a master regulator of retinal health, reshaping our understanding of #AMD, #OxidativeStress & the #GutEyeAxis. #Ophthalmology #Retina #EyeHealth #VisionScience buff.ly/Fvi4Q0H

Congrats to @prof-clark.bsky.social for the 2025 #Svar Complement Excellence Award at ICW Brisbane ! This Award is an annual honor for outstanding international contributions to complement science. 💪👏 @unituebingen.bsky.social @tueneurocampus.bsky.social www.eye-tuebingen.de?tx_news_pi1%...

Pleased to share that I will be talking at this year's Complement Based Drug Development Summit 1st-3rd Dec, in Boston US. Join us for the latest developments and future visions for complement therapeutics! buff.ly/RqA9bfm #complement #drugdevelopment #innovation

First-ever use of Adaptive Optics Transscleral Flood Illumination (AO-TFI) reveals 4 distinct retinal phenotypes in AMD, opening new paths for earlier detection and precision monitoring. #AMD #Ophthalmology #AdaptiveOptics #Retina #MedicalImaging buff.ly/FrxgHDX

It’s a huge honor to receive one of this years SVAR Complement Excellence Award 2025! Thank you so much for this recognition of our work studying ECM-driven immunity! @eye-tuebingen.bsky.social #ICW2025 #AMD #ophthalmology #complement

This doesn't look good - I remember when Merck committed to a +£1Billion investment in the UK was touted as a Brexit win. Merck executes its own Brexit, moving all R&D operations out of UK

AI eye scans in GP clinics hit 93% accuracy detecting diabetic retinopathy—real-world proof that accessible, instant screening can transform early detection and patient care. buff.ly/kilZWTi #AI #DigitalHealth #DiabeticRetinopathy #HealthTech #Early

Striking shifts in FH N-glycans appear in HUS patients without altering core function, raising big questions about whether AMD risk variants might also shape complement glycosylation. #AMD #complement #glycans #glycobiology #risk buff.ly/mPYgbVB

New real-world data show avacincaptad pegol (Izervay) is safe in GA, with no inflammation or endophthalmitis and only ~6% annual CNV risk—reassuring results beyond clinical trials. #GeographicAtrophy #AvacincaptadPegol #Ophthalmology #RealWorldEvidence #Innovation buff.ly/mSnVtjg

🚨 PhD Positions Alert!🚨 Want to join a dynamic initiative between Europe's two leading centres of Ophthalmology? Then apply for a PhD opportunity as part of our Limits2Vision research programme - buff.ly/Ewv0g2k

New imaging shows hyporeflective clumps in AMD eyes move at microglia-like speeds, unveiling a dynamic biomarker that could transform how we track disease progression. #AMD #Ophthalmology #AdaptiveOptics #Biomarkers #VisionScience buff.ly/4uKVDsE

For the first time in vivo, researchers show that C-reactive protein dissociation into monomeric CRP drives inflammation and choroidal neovascularization in AMD—revealing a novel therapeutic target. #AMD #CRP #VisionResearch #Inflammation #Ophthalmology buff.ly/NqCkRkX

New research shows that HTRA1-driven proteolysis directly induces retinal degeneration in AMD, uncovering RBP3 as a novel substrate and potential therapeutic target. #AMD #HTRA1 #VisionResearch #TherapeuticTargets #Ophthalmology buff.ly/D9LsDVO

🌍 Discover how mapping sialoglycoconjugates in the human retina opens new doors for ocular disease therapies buff.ly/YPEg5kj #Ophthalmology #RetinaResearch #AMD #Biomarkers #TherapeuticInnovation #FutureOfMedicine

🚨 BREAKTHROUGH for vision loss: The FDA just approved Encelto, the first-ever treatment for Macular Telangiectasia type 2 (MacTel) - a living implant that protects vision from inside the eye. #Encelto #MacTel #MedTech buff.ly/9Le7LSv

🚨 Your next eye exam might save your heart. A simple retinal image—taken in less than a minute—can now predict your 10-year risk of heart attack, stroke, or CV death with 70% accuracy, thanks to AI #AIinHealthcare #DigitalHealth #CardiovascularHealth buff.ly/g8E44LX

Gene therapy delivering anti-VEGF shows promise in treating DME, offering hope to patients tired of regular IVT injections. Despite challenges in the gene therapy field, the ocular domain proves safe for this technology. #genetherapy #CNV #DME #aflibercept buff.ly/b0gFsak

Single-vesicle proteomics identifies CD35+ urinary EVs as a novel biomarker for early detection of sepsis-associated AKI (AUC ≈ 0.89). 💡 Podocyte-derived, complement-rich, & more accurate than TIMP-2*IGFBP7. 📈 Diagnostic + prognostic power. buff.ly/JFFVkpY

Neutrophils don’t help repair laser-induced retinal damage: microglia do it alone! Using live imaging, researchers show microglia rapidly migrate to injury while neutrophils stay in the vessels. #Neuroimmunology #Retina #Microglia #eLife #Science

Boehringer's growing interest in the ophthalmic space, with a focus on sustained ocular drug delivery, is encouraging to see. They aim to use Re-Vana’s drug delivery technology in a $1B deal for their ophthalmic pipeline. #ophthalmology #drugdelivery

New in RA therapy: bispecific antibodies target local complement activation without systemic suppression. They bind carbamylated proteins & recruit native regulators (Factor H/C4BP) to halt joint inflammation. #Rheumatology #RA #Immunology #Biologics buff.ly/KWLPMoa

New study shows why not all #DME responds to anti-VEGF. CMD (cystoid macular degeneration) resists treatment—linked to apoptosis, complement activation & lipid metabolism. DRT/CME fare better, tied to Wnt & ECM signalling. #Ophthalmology #Retina #Diabetes buff.ly/Jhot42I

🧬 New study links genetic risk scores to retinal damage in AMD. Using OCT imaging, researchers found: 🔹 Complement genes → early signs (drusen) 🔹 ARMS2/HTRA1 → advanced atrophy 🔹 Global scores predict disease severity #AMD #Genetics #Ophthalmology buff.ly/2tz6L0o

New discovery: FHR1, a complement system protein, plays a surprising role in helping macrophages clear dead cells (efferocytosis). #FHR1 #Immunology #Macrophages #Proteomics #Biotech #ComplementSystem #SingleCell buff.ly/KkCkG9e

This is an...interesting approach - inravenous (IV) delivery of an anti-PRL3 humanised antibody to treat CNV in wet AMD 😳 . Some good pre-clinical data in CNV models, but I wonder about IV delivery for treating eye disease. #CNV #cancer #AMD

recent study uses AI to assess risk genotypes from AMD fundus images. However, their genetic dataset lacks recent risk SNPs, such as CFH intronic SNP rs10922109. Promising start but needs to include the latest genetic risk factors. #AMD #AI #CFH #ARMS2 buff.ly/bpKp6am

Review highlights new immune checkpoint found in the eye. Loss of sialylation triggers complement-mediated damage in AMD. Preclinical rescue via polysialic acid delivery = preserved retinal cells + reduced inflammation. #Biotech #Immunotherapy #AMD buff.ly/17SpdAK

Recent study shows FH serum as a marker for Cutaneous Squamous Cell Carcinoma progression. However, their FH baseline of 122–895 pg/ml seems off; typical levels are 250-750 ug/ml. Why the discrepancy? #complement #FH #cancer #prognosis buff.ly/fLik0Vh

Intravitreal injections save vision—but sterile intraocular inflammation is a growing concern. Linked to brolucizumab & complement inhibitors, it can mimic infection & cause serious damage. Timely diagnosis + steroids = key. #Ophthalmology #Retina buff.ly/JCZoWf6

Alcon has acquired the Valeda photobiomodulation devise, using low-level light to help stimulate mitochondrial activity in the cells of the retina, marking a pivotal expansion into non-invasive therapies for early and intermediate dry AMD. #DryAMD

Rallybio is exiting its Recursion/Exscientia partnership on REV102, to refocus on its C5 inhibitor, RLYB116. Will the once-weekly subcutaneously delivered C5 inhibitor sufficiently down regulate systemic complement? #C5inhibitor #Biotech #RareDisease

First patient dosed with PulseSight's non viral vectorised therapy to overexpress transferrin to treat GA in AMD. How well this elctro-transfection technique acts as a delivery method for non-viral gene therapies? #AMD #GA #genetherapy

Interesting study describing the potential use of a C3d-antibody to hone therapeutic delivery to the kidney's of aHUS patients. A number of advantages over systemic targeting of complement for an organ-specific disease. #aHUS #CR1 #complement buff.ly/nISOz9S

4DMT puts everything on the line for its bicistronic approach delivering aflibercept and siRNA against VEGF-C. Does this include pausing its 4D-175 asset delivering shortened FH in GA? #wetAMD #CNV #aflibercept #AAV

Cool study investigating the role of FHR-1 in AMD - with comparisons to murine FHR1 homologue too. Appears to have subtly different localisation profile compared to FHR-2, -4, and -5 as seen in other studies, but its there! #AMD #FHR #ophthalmology buff.ly/UkgTd7s

EU okays extended treatment interval for Bayer, Regeneron's higher-dose Eylea buff.ly/4Yn1bT6 This will move the goalposts for assets whose USP is less frequent dosing. How much better are they going to have to be now? Once a year? #wetAMD #antiVEGF #eylea

New insights into AMD: A recent study maps the retinal sialome and finds reduced sialic acid at the Bruch's membrane–choroid interface in AMD eyes—potentially impacting complement regulation via factor H (FH). #AMD #Ophthalmology #ComplementSystem buff.ly/jvrGu4F

Despite the layoffs and lab closures at BlueRock, their ocular asset OpCT-001, an investigational iPSC-derived cell therapy, should not be affected. OpCT-001 entered phase I/II trials earlier this year. #celltherapy #ophthalmology #clinicaltrials

Stuart Therapeutics’ dry eye drug ST-100 failed its Phase 3 trial. Despite promising Phase 2 data, the novel collagen-repair eyedrop didn’t meet endpoints. They plan another study—but it’s a tough road in #DryEyeDisease R&D. #Biotech #Ophthalmology

ForSight Robotics raises $125M to bring robotic precision to cataract surgery. ORYOM® platform uses AI + robotics to perform ultra-steady eye surgery—10× more precise than the human hand. #MedTech #AI #SurgicalRobotics #Ophthalmology

🇬🇧 The UK wants to be a top 3 global life sciences economy by 2035. How? 🔬 Supercharge R&D & NHS trials 🏗️ Expand labs + upskill 145K workers 💼 £2.5B Innovation Fund 🌐 Global deals + big pharma hubs #LifeSciences #Biotech #UKInnovation #ClinicalTrials buff.ly/7xMbY7g